Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
At the direction of the U.S. Food and Drug Administration (FDA), Biogen Inc. has added a warning of potential liver injury to the label for its multiple sclerosis medication Tecfidera.
According to the FDA warning, “[c]linically significant cases of liver injury have been reported in patients treated with Tecfidera in the postmarketing setting.
The onset has ranged from a few days to several months after initiation of treatment with Tecfidera.”
Liver injury information can be found in a warning section under prescribing information on the website tecfidera.com.
Tecfidera, formerly known as BG-12, is a fumaric acid derivative that was formulated specifically for use by people with multiple sclerosis.
Although exactly the way it works is not fully understood, it is thought to inhibit immune cells and molecules and may have antioxidant properties to provide protection against damage to the brain and spinal cord.
Common side effects associated with Tecfidera include flushing, usually described as redness, itching, or rash; and stomach problems such as nausea, vomiting, diarrhea, stomach pain, and indigestion.
More severe side effects include allergic reactions; PML, a rare brain infection that leads to death or disability; decreases in white blood cell count; and liver problems.
There have been 14 cases of liver injury reported with Tecfidera use, but the problems resolved when patients stopped taking the medication and none required hospitalization.
Symptoms of liver injury include significant increases above normal of serum aminotransferases and bilirubin, according to Biogen.
Because liver enzyme monitoring is typical with many MS drugs, it is not anticipated that the new warning will present an added burden to prescribing physicians.
It remains to be seen whether or not the warning will temper sales projections for Tecfidera, which is the world’s top-selling MS medication and accounts for about one-third of Biogen’s total revenue.
Biogen recently announced an eight percent increase in the U.S. price of Tecfidera, effective January 1, and experts have forecasted that Tecfidera sales will be more than $4 billion in 2017.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Fresenius Kabi USA, LLC has announced a corrective Class I recall of an infusion pump software, LVP Software, that runs on the Ivenix Infusion System (IIS). Initiated by the firm on March 7, 2024, the action comes after multiple software anomalies were identified and found
According to the FDA, 20-ounce packages of “King Kullen Broccoli Cutlets with Bread Crumbs and Parmesan” have been recalled by New Haven, Connecticut-based Gracie’s Kitchen due to the potential presence of undeclared sesame and wheat. Individuals who live with allergies to either allergen are advised
The FDA is warning consumers of a Class I recall of Boston Scientific’s Obsidio Comformable Embolic because the device has been shown to present a risk for increased bowel ischemia when used for lower GI (gastrointestinal) bleeding, or acute colonic bleeding. As a pre-mixed embolic